Baidu
map

国家药监局修订速效救心丸说明书,过敏者慎用

2021-01-21 医谷网 医谷网

近日,国家药监局于官网发布《关于修订速效救心丸说明书的公告》(以下简称“公告”)提出,根据药品不良反应评估结果,为进一步保障公众用药安全,国家药品监督管理局决定对速效救心丸说明书的警示语、不良反应、禁

近日,国家药监局于官网发布《关于修订速效救心丸说明书的公告》(以下简称“公告”)提出,根据药品不良反应评估结果,为进一步保障公众用药安全,国家药品监督管理局决定对速效救心丸说明书的警示语、不良反应、禁忌和注意事项进行统一修订。

根据《速效救心丸说明书修订要求》显示,警示语应当包括孕妇禁用;不良反应项应当增加监测数据显示,本品可见以下不良反应:恶心、呕吐、口干、头痛、头晕、皮疹、瘙痒、潮红、乏力、过敏及过敏样反应等。禁忌项应当增加孕妇禁用,对本品及所含成份过敏者禁用。注意事项项应当增加过敏体质者慎用。

公告明确要求,本品的上市许可持有人应依据《药品注册管理办法》等有关规定,按照相应说明书修订要求(见附件)修订说明书,于2021年4月13日前报省级药品监督管理部门备案。

修订内容涉及药品标签的,应当一并进行修订;说明书及标签其他内容应当与原批准内容一致。在备案之日起生产的药品,不得继续使用原药品说明书。药品上市许可持有人应当在备案后9个月内对已出厂的药品说明书及标签予以更换。

同时,公告指出药品上市许可持有人应当对新增不良反应发生机制开展深入研究,采取有效措施做好药品使用和安全性问题的宣传培训,指导医师和患者合理用药。

临床医师应当仔细阅读本品说明书的修订内容,在选择用药时,应当根据新修订说明书进行充分的获益/风险分析。

患者用药前应当仔细阅读药品说明书,使用处方药的,应严格遵医嘱用药。

省级药品监督管理部门应当督促行政区域内本品的药品上市许可持有人按要求做好相应说明书修订和标签、说明书更换工作,对违法违规行为依法严厉查处。

附件

速效救心丸说明书修订要求

一、警示语应当包括:

孕妇禁用

二、【不良反应】项应当增加:

监测数据显示,本品可见以下不良反应:恶心、呕吐、口干、头痛、头晕、皮疹、瘙痒、潮红、乏力、过敏及过敏样反应等。

三、【禁忌】项应当增加:

1.孕妇禁用。

2.对本品及所含成份过敏者禁用。

四、【注意事项】项应当增加:

过敏体质者慎用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2037505, encodeId=c2e7203e5057f, content=<a href='/topic/show?id=ee9c9406868' target=_blank style='color:#2F92EE;'>#过敏者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94068, encryptionId=ee9c9406868, topicName=过敏者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Mon Jun 28 02:38:27 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301734, encodeId=7b4e1301e3424, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429269, encodeId=b9d1142926957, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507217, encodeId=5038150e21730, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592197, encodeId=59de159219eee, content=<a href='/topic/show?id=d21f94946ce' target=_blank style='color:#2F92EE;'>#速效救心丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94946, encryptionId=d21f94946ce, topicName=速效救心丸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce0e18095413, createdName=jj000007, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2037505, encodeId=c2e7203e5057f, content=<a href='/topic/show?id=ee9c9406868' target=_blank style='color:#2F92EE;'>#过敏者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94068, encryptionId=ee9c9406868, topicName=过敏者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Mon Jun 28 02:38:27 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301734, encodeId=7b4e1301e3424, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429269, encodeId=b9d1142926957, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507217, encodeId=5038150e21730, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592197, encodeId=59de159219eee, content=<a href='/topic/show?id=d21f94946ce' target=_blank style='color:#2F92EE;'>#速效救心丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94946, encryptionId=d21f94946ce, topicName=速效救心丸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce0e18095413, createdName=jj000007, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=)]
    2021-01-23 xuyu
  3. [GetPortalCommentsPageByObjectIdResponse(id=2037505, encodeId=c2e7203e5057f, content=<a href='/topic/show?id=ee9c9406868' target=_blank style='color:#2F92EE;'>#过敏者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94068, encryptionId=ee9c9406868, topicName=过敏者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Mon Jun 28 02:38:27 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301734, encodeId=7b4e1301e3424, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429269, encodeId=b9d1142926957, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507217, encodeId=5038150e21730, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592197, encodeId=59de159219eee, content=<a href='/topic/show?id=d21f94946ce' target=_blank style='color:#2F92EE;'>#速效救心丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94946, encryptionId=d21f94946ce, topicName=速效救心丸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce0e18095413, createdName=jj000007, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2037505, encodeId=c2e7203e5057f, content=<a href='/topic/show?id=ee9c9406868' target=_blank style='color:#2F92EE;'>#过敏者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94068, encryptionId=ee9c9406868, topicName=过敏者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Mon Jun 28 02:38:27 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301734, encodeId=7b4e1301e3424, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429269, encodeId=b9d1142926957, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507217, encodeId=5038150e21730, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592197, encodeId=59de159219eee, content=<a href='/topic/show?id=d21f94946ce' target=_blank style='color:#2F92EE;'>#速效救心丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94946, encryptionId=d21f94946ce, topicName=速效救心丸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce0e18095413, createdName=jj000007, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2037505, encodeId=c2e7203e5057f, content=<a href='/topic/show?id=ee9c9406868' target=_blank style='color:#2F92EE;'>#过敏者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94068, encryptionId=ee9c9406868, topicName=过敏者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Mon Jun 28 02:38:27 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301734, encodeId=7b4e1301e3424, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429269, encodeId=b9d1142926957, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507217, encodeId=5038150e21730, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592197, encodeId=59de159219eee, content=<a href='/topic/show?id=d21f94946ce' target=_blank style='color:#2F92EE;'>#速效救心丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94946, encryptionId=d21f94946ce, topicName=速效救心丸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce0e18095413, createdName=jj000007, createdTime=Sat Jan 23 11:38:27 CST 2021, time=2021-01-23, status=1, ipAttribution=)]

相关资讯

用速效救心丸治疗急性心梗易致人死亡?

导语:有人做过统计,每100 个猝死的人里面,有80 ~ 90 个是由于急性心梗引起的。通常,90%的急性心梗引起的猝死都发生在医院以外的场合,而且大多数患者都是在发病后15 分钟之内死亡的。世界上,平均每秒钟就有1 个人死于心梗。一个人一旦发生急性心梗,如果没有得到及时救治,随时就可危及生命,特别紧急的情况下,会即刻丧命。很多人都来不及交代后事,甚至有的人都还没反应过来自己是发生了什么事,就永远

选速效救心丸,还是硝酸甘油?(修订)

硝酸甘油和速效救心丸,都称得上是心绞痛患者的“救命药”。那么,在心绞痛急性发作时,到底是应该选用硝酸甘油还是速效救心丸?这两种药之间究竟怎样区别呢?一、两种药均可用于心绞痛急性发作心绞痛为冠状动脉血流量不能满足心脏需要,心肌急剧的、暂时的缺血、缺氧所引起。硝酸甘油片和速效救心丸均可用于冠心病心绞痛的治疗及预防(药品说明书)。硝酸甘油片硝酸甘油是救治心绞痛发作的首选药物。可用于冠心病心绞痛的治疗及预

速效救心丸治疗冠心病中国专家共识

近年来,随着人们生活方式的变化和人民生活水平的提高、人口城镇化及老龄化进程的加快,糖尿病、高血压、高血脂和肥胖等心脑血管病危险因素的发病率迅速增加。冠心病已经成为我国目前最大的卫生健康问题之一,冠心病的治疗给家庭和社会带来了巨大的经济负担,中成药在冠心病的预防、治疗、急救中有着重要的作用。速效救心丸为《中华人民共和国药典》第一个纯中药滴丸制剂,由我国著名药学专家章臣桂教授研制开发,自1982年上市

外泌体介导的速效救心丸在缺血损伤心肌中的保护作用

目前对于AMI的治疗(药物、溶栓及介入等)旨在保留剩余的心肌细胞并降低与AMI病理学后果相关的发病率和病死率,即使早期进行血运重建也只可能挽救约50%的梗死面积。因此,IHD再生疗法是新近的研究热点之一。

Baidu
map
Baidu
map
Baidu
map